Pharma major Lupin Limited has acquired privately held Gavis Pharmaceuticals LLC for $880 million. The acquisition enhances Lupin’s scale in the U.S. generics market and also broadens its pipeline in dermatology, controlled substance products and other high-value and niche generics. Gavis brings to Lupin a U.S.-based R&D organization, which would complement Lupin’s Coral Springs, FL inhalation R&D center. Gavis’s NJ-based manufacturing facility will become Lupin’s first...